Evidence map›Paper›PMID 34351607›Full record

ReviewClinical drug investigation2021

Tirbanibulin: Topical Treatment for Actinic Keratosis.

Anna H Dlott, Anthony J Di Pasqua, Sara A Spencer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical drug investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Anna H DlottDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, State University of New York, PO Box 6000, Binghamton, NY, 13902-6000, USA.
Anthony J Di PasquaDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, State University of New York, PO Box 6000, Binghamton, NY, 13902-6000, USA. dipasqua@binghamton.edu.
Sara A SpencerDepartment of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, State University of New York, PO Box 6000, Binghamton, NY, 13902-6000, USA. saspence@binghamton.edu.ORCID http://orcid.org/0000-0001-7565-1340
Binghamton University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We review here the pharmacology, pharmacokinetics, efficacy, dosage and administration, and place in therapy of tirbanibulin for the treatment of actinic keratosis (AK). A literature search using PubMed was conducted using the terms tirbanibulin (tirbanibulin) and actinic keratosis from September 2014 to February 2021. All English-language articles evaluating tirbanibulin were analyzed for this review. Tirbanibulin was granted approval for the treatment of AK of the face or scalp as a first-line therapy. It is administered at a dose of 2.5 mg in 250 mg of white or off-white ointment for a 25 cm

Indexed as

Keratosis, ActinicAdministration, TopicalHumansOintmentsProtein Kinase InhibitorsTreatment OutcomeOintmentsProtein Kinase Inhibitors

Identifiers

PMID34351607
OpenAlexW3191486660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.